Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322821 | 0.95 | KDM4E (0.56) | KDM4EMEN1KMT2ALMNATSHR | |
| SCHEMBL5239830 | 0.95 | KDM4E (0.56) | KDM4EMEN1KMT2ALMNATSHR | |
| SCHEMBL5239823 | 0.95 | KDM4E (0.56) | KDM4EMEN1KMT2ALMNATSHR | |
| SCHEMBL24322617 | 0.95 | KDM4E (0.56) | KDM4EMEN1KMT2ALMNATSHR | |
| SCHEMBL5241411 | 0.95 | KDM4E (0.56) | KDM4EMEN1KMT2ALMNATSHR | |
| SCHEMBL9801414 | 0.79 | LMNA (0.51) | KDM4EMEN1KMT2ALMNATSHR | |
| SCHEMBL27209994 | 0.79 | LMNA (0.51) | KDM4EMEN1KMT2ALMNATSHR | |
| SCHEMBL5242890 | 0.79 | KDM4E (0.47) | KDM4EMEN1KMT2ATSHRNPSR1 | |
| SCHEMBL5240182 | 0.79 | KDM4E (0.47) | KDM4EMEN1KMT2ATSHRNPSR1 | |
| SCHEMBL5242690 | 0.79 | KDM4E (0.47) | KDM4EMEN1KMT2ATSHRSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | KDM4E 4426/4885MEN1 786/4885KMT2A 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.